About HLT, Inc.

HLT, Inc., is committed to delivering leading edge transcatheter valve therapy by developing technology intended to provide more control during the implant procedures with predictable patient outcomes.

  • To move heart valve disease therapy forward, we believe valve technology must conform to the native valve anatomy.
  • We are focused on addressing additional clinical needs. Transcatheter valve therapies are gaining broad clinical acceptance and the outlook is very promising, yet opportunities remain in valve design and procedural advancement, particularly optimizing implant position. The Meridian® Valve is intended to address these clinical needs.
  • We design our therapies with the intent of providing physicians both the precision to control and the flexibility to adjust throughout the procedure.

About transcatheter aortic valve replacement (TAVR) and aortic stenosis

Transcatheter aortic valve replacement (TAVR) treats aortic stenosis, a narrowing of the aortic valve that obstructs blood flow from the heart. Aortic stenosis is one of the most frequent heart valve diseases.

Surgical aortic valve replacement (SAVR) is the current standard treatment for patients with severe symptomatic aortic stenosis. However, many high-risk patients with aortic stenosis are not candidates for surgery. A less-invasive approach, transcatheter aortic valve replacement, is a way to replace the diseased aortic valve without open heart surgery for this patient population. The TAVR procedure involves making a small incision in the leg and navigating a replacement valve into the heart. Today, it is estimated that more than 200,000 patients with severe aortic stenosis are potential candidates for TAVR.

TAVR is also referred to as TAVI, transcatheter aortic valve implantation.

Clinical Trials

The company is currently pursuing clinical trials for the Meridian® Valve.



HLT, Inc.’s parent company, the Bracco Group, headquartered in Milan, Italy, is a leader in diagnostic imaging.